Cargando…
FTY720 in immuno-regenerative and wound healing technologies for muscle, epithelial and bone regeneration
In 2010, the FDA approved the administration of FTY720, S1P lipid mediator, as a therapy to treat relapsing forms of multiple sclerosis. FTY720 was found to sequester pro-inflammatory lymphocytes within the lymph node, preventing them from causing injury to the central nervous system due to inflamma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213316/ https://www.ncbi.nlm.nih.gov/pubmed/37250137 http://dx.doi.org/10.3389/fphys.2023.1148932 |